This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
NVRO Stock May Gain on the FDA Approval of Its HFX AdaptivAI Platform
by Zacks Equity Research
Nevro announces the FDA approval and limited market release of HFX iQ with HFX AdaptivAI.
Reasons to Retain Veeva Systems Stock in Your Portfolio Now
by Zacks Equity Research
VEEV's robust product portfolio raises optimism about the stock. However, stiff competition and escalating costs are concerning.
ITGR Shares May Gain on the Completion of Irish Facility Expansions
by Zacks Equity Research
Integer Holdings announces the completion of its Irish facility expansions in Galway and New Ross to support growth.
Stryker Shares May Gain on the Completion of the Acquisition of NICO
by Zacks Equity Research
SYK completes the acquisition of NICO to strengthen its portfolio of solutions for tumor resection and the treatment of ICH.
SNN Stock Rises on the Completion of First Case With CATALYSTEM System
by Zacks Equity Research
Smith & Nephew announces the completion of the first case using the CATALYSTEM Primary Hip System.
Here's Why Hold Strategy is Apt for ABM Industries Stock Now
by Zacks Equity Research
ABM has consistently demonstrated its commitment to rewarding shareholders through dividends and share buybacks.
Here's Why You Should Retain McKesson Stock in Your Portfolio Now
by Zacks Equity Research
MCK's strategic collaborations and strength in Biologics raise optimism about the stock.
GEHC Stock Rises as FDA Clears MIM Software's Centiloid Tool
by Zacks Equity Research
GE Healthcare's MIM Software announces the receipt of FDA clearance for its Centiloid scaling tool to perform PET-based amyloid imaging.
CAH Stock May Gain Following the Distribution Agreement With Telix
by Zacks Equity Research
Cardinal Health and Telix announce an agreement selecting the former as a commercial radiopharmaceutical distributor to supply finished unit doses of Telix's Zircaix.
Here's Why You Should Retain Accuray Stock in Your Portfolio Now
by Zacks Equity Research
ARAY's solid product demand and revenue growth raise optimism about the stock.
NSPR Stock Declines Despite PMA Application Submission for CGuard
by Zacks Equity Research
InspireMD announces the submission of the PMA application to the FDA for marketing approval of the CGuard Prime EPS.
CVRX Stock Gains on Unveiling of Barostim's Positive Study Data
by Zacks Equity Research
CVRx announces the publication of positive study data for its Barostim therapy.
Merit Medical Gains 26.4% Year to Date: What's Driving the Stock?
by Zacks Equity Research
MMSI's shares gain on the back of strength in its Cardiovascular segment and a robust product portfolio.
SNN Stock Declines Despite the Launch of Its Patient-Matched Guides
by Zacks Equity Research
Smith & Nephew announces the launch of its TOTAL ANKLE Patient-Matched Guides to plan and perform total ankle replacement procedures.
ELEVATE Benefits ABM's Organic Growth Despite Rising Expenses
by Zacks Equity Research
ABM Industries focuses on providing transparent and efficient offerings to its clients and improving its talent management system.
Avanos Medical Stock May Gain From Brand Partnership With NFL
by Zacks Equity Research
AVNS' GAME READY announces a paid partnership with NFL defensive end and San Francisco 49ers star, Nick Bosa.
Solventum Shares May Gain on the Launch of Its New V.A.C Therapy
by Zacks Equity Research
SOLV announces the launch of its V.A.C. Peel and Place Dressing for providing efficient and effective care in case of negative pressure wound therapy.
Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now
by Zacks Equity Research
PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.
ABM Industries Shares Barely Move After Reporting Q3 Earnings Beat
by Zacks Equity Research
ABM's technical solutions, aviation and education segments reported y/y revenue growth in third-quarter fiscal 2024.
iRhythm Stock Gains Following Favorable Zio Monitor Study Data
by Zacks Equity Research
IRTC announces initial findings demonstrating the superior real-world performance of the next-generation Zio LTCM Monitor at the HRX 2024 meeting.
Fresenius Medical Care Stock Rises on NxStage VersiHD Launch
by Zacks Equity Research
FMS introduces NxStage VersiHD with GuideMe Software to simplify home dialysis and grow its patient base in the United States.
iRhythm Stock May Gain on Its Latest Deal With BioIntelliSense
by Zacks Equity Research
IRTC announces an exclusive license agreement with BioIntelliSense to develop and commercialize certain patented technology assets within AMC.
DENTSPLY SIRONA Stock May Gain on the Launch of Primescan 2
by Zacks Equity Research
XRAY introduces its new-generation intraoral scanner, Primescan 2, to provide effective and efficient care and comfort to patients.
McKesson Shares Fall Following Sale of Rexall, Well.ca to Birch Hill
by Zacks Equity Research
MCK announces the sale of its Canada-based Rexall and Well.ca businesses to Birch Hill Equity Partners, aligning with its strategy to grow oncology and biopharma services.
Are Business Services Stocks Lagging ABM Industries (ABM) This Year?
by Zacks Equity Research
Here is how ABM Industries (ABM) and CRA International (CRAI) have performed compared to their sector so far this year.